Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.
Kunal Girotra
Advertisement
Senior Manager, Strategy & Enablement, Pfizer
Articles by Kunal Girotra
Advertisement
Latest Updated Articles
Beyond the Data: Making HCP Analytics Actually Work for Commercial TeamsFebruary 21st 2025
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
2
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
3
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
4
FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy
5